Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QGC001 versus placebo in essential hypertension
2014-003071-37Phase 2Completed
- Sponsor
- Quantum Genomics
- Start
- Jun 2015
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of firibastat in essential hypertension (2 arms), sponsored by Quantum Genomics. Primary endpoint: Change from baseline in daytime mean systolic blood pressure. Started Jun 2015; status: completed.
02
Drugs
firibastat
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2014-003071-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003071-37.